AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 251 min read$ANIX

Titterton Lewis H jr purchased $132K of ANIX

Titterton Lewis H jr purchased 49,036 shares of Anixa Biosciences Inc (ANIX) at $2.69 ($0.13M total) on 2026-09-23.

Original reporting
SEC EDGAR · Titterton Lewis H jr
Published Sep 25, 2026, 12:39 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 25, 2026, 1:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ANIX
Bullish
medium confidence
Mentioned
$ANIX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANIXBullishLow
01

Why it matters

The filing provides the first public disclosure of this insider purchase, offering a fresh data point for traders.

02

Market read

Direct insider buying may influence short‑term trading decisions for ANIX.

03

What to watch

The purchase amount is small; larger institutional activity would be more material.

Relevance 5/10Novelty 4/10Timing: post‑market filing on 2026‑09‑23

Background

Form 4 filings disclose insider transactions; director purchases are monitored for potential signals.

Company-level read

Ticker impact

$ANIXBullishMedium confidence
Context

Director Titterton Lewis H Jr bought 49,036 shares for $131,907, increasing his stake to over 1 million shares.

Expected impact

Modest upward pressure as market may view the purchase favorably.

Evidence & confidence

The purchase size is modest relative to market cap, but director involvement adds credibility.

Market effects

Sector

May slightly boost sentiment in the biotech sector as insider buying is viewed positively.

Regional

Limited to U.S. markets where ANIX trades.

Global

Minimal global impact.

Counterpoint

What could challenge this read

Insider purchase could be routine portfolio rebalancing, not a strong bullish signal.

Key entities

  • Company
    Anixa Biosciences Inc

    Biotech firm listed on NASDAQ under ticker ANIX.

  • Individual
    Titterton Lewis H Jr

    Director of Anixa Biosciences who made the purchase.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ANIX insider trading history →

Related articles

OCT 6
$ANIXMedAI 8/10

H.C. Wainwright reiterates Buy on Anixa stock, $6 target on trial data

H.C. Wainwright reiterated a Buy rating and $6 target on Anixa Biosciences (ANIX) after positive trial data. The stock trades at $2.95, with analysts' targets ranging from $6 to $14. The company reported stable disease in a patient from its Phase 1 trial of lira-cel for ovarian cancer. ANIX holds a strong financial position with a current ratio of 8.54 and more cash than debt. The firm expects further trial updates soon.

investing.com2 min
OCT 5
$ANIXMed

Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences reported that a patient in its Phase 1 trial for ovarian cancer CAR-T therapy showed stable disease 3 months post-treatment. No dose-limiting toxicities were observed. The trial, conducted at Moffitt Cancer Center, aims to assess safety and preliminary efficacy of lira-cel, a novel CAR-T therapy targeting FSHR. Multiple patients have survived over a year, with one exceeding two years.

prnewswire.com2 min
OCT 1
$ANIXMedAI 8/10

Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences (NASDAQ: ANIX) announced the second patient has been treated in the fifth cohort of its Phase 1 clinical trial for recurrent ovarian cancer. The trial, conducted at Moffitt Cancer Center, evaluates a novel FSHR-targeted CAR-T therapy. Patients in the fifth cohort receive 1×10⁷ CAR-positive cells/kg following lymphodepletion. No dose-limiting toxicities have been observed, and multiple patients have survived over a year, with one surpassing two years.

prnewswire.com2 min
SEP 11
$ANIXMedAI 8/10

RedChip Companies, Inc.: Anixa Biosciences and Nexalin Technology Interviews to Air Nationally on the RedChip Small Stocks, Big Money Show on CNBC and Bloomberg TV

RedChip Companies will air interviews with Anixa Biosciences (NASDAQ:ANIX) and Nexalin Technology (NASDAQ:NXL) on Bloomberg TV and CNBC. Anixa is developing a breast cancer vaccine, while Nexalin focuses on neurostimulation for mental health. Both companies are preparing for key trials and commercialization efforts.

finanznachrichten.de2 min
OCT 7
$LWAYLow

Divisadero Street Capital Management, LP (Zolezzi William) purchased $2.2M of LWAY (indirect holdings)

Divisadero Street Capital Management, LP purchased 103,684 indirectly-held shares of Lifeway Foods, Inc. (LWAY) at an average of $20.92 ($20.80–$21.09, $2.17M total) across 3 trades over 2026-10-02 to 2026-10-06. Filed jointly with Divisadero Street Partners GP, LLC (10% owner), Zolezzi William (10% owner), Divisadero Street Partners, L.P. (10% owner) and Divisadero Street Capital, LLC (10% owner).

SEC EDGAR1 min